TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33730841

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Bruton's tyrosine kinase inhibitors
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: GEP-based prognostic models
Number of subjects: 337

Group type: COMPARATOR
Intervention: Established prognostic factors (including TP53 and IGHV gene mutation status)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Independent prognostic impact of treatment, β2-microglobulin and del(17p)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Independent prognostic impact of treatment, del(11q), del(17p) and SF3B1 mutation
Number of subjects: 337
Study: 33730844

Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily until disease progression or intolerance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 60
Study: 33731014

Group type: EXPERIMENTAL
Intervention: Participation at investigator teleconferences
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Public holidays
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Reaching 80% of the site's recruitment target
Number of subjects: 766
Study: 33731212

Group type: EXPERIMENTAL
Intervention: Tailored discharge teaching by trained teaching nurses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation strategies from the Theoretical Domains Framework and the Behavior Change Wheel
Number of subjects: 0
Study: 33731219

Group type: EXPERIMENTAL
Intervention: Physical Activity on Prescription (PAP)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combination of PAP and mindfulness
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 88
Study: 33731327

Group type: EXPERIMENTAL
Intervention: Serological testing for SARS-CoV-2
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Symptoms in children
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Clustering of seropositive children
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Class level variance in seropositivity
Number of subjects: 2603
Study: 33731366

Group type: EXPERIMENTAL
Intervention: Chromatin accessibility and gene expression analysis using ATAC-seq on biobanked specimens.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhancer activity analysis.
Number of subjects: 0
Study: 33731384

Group type: EXPERIMENTAL
Intervention: Hiatal hernia (HH) identified via non-contrast CT
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor use
Number of subjects: 3200

Group type: EXPERIMENTAL
Intervention: 10-year follow-up of 75 participants with HH
Number of subjects: 3200
Study: 33731427

Group type: EXPERIMENTAL
Intervention: Phone follow-up at 30 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phone follow-up at 30 days, 60 days, 6 months, and 12 months
Number of subjects: 0
Study: 33731738

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) radiomics
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Predicted early responders (ER)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Predicted late responders (LR)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Predicted persistent/progressive disease (PD)
Number of subjects: 59
Study: 33731806

Group type: EXPERIMENTAL
Intervention: Nephrology follow-up
Number of subjects: 2041

Group type: EXPERIMENTAL
Intervention: Family physician or pediatrician follow-up
Number of subjects: 2041

Group type: EXPERIMENTAL
Intervention: Non-nephrology specialist follow-up
Number of subjects: 2041

Group type: EXPERIMENTAL
Intervention: Stage 2-3 AKI nephrology follow-up
Number of subjects: 2041

Group type: COMPARATOR
Intervention: Inpatient nephrology consult
Number of subjects: 2041

Group type: COMPARATOR
Intervention: Kidney admission diagnosis
Number of subjects: 2041

Group type: COMPARATOR
Intervention: AKI non-recovery by discharge
Number of subjects: 2041
Study: 33731991

Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol
Number of subjects: 4819
Study: 33732196

Group type: EXPERIMENTAL
Intervention: Matching to psychotherapy preference
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard psychotherapy
Number of subjects: 0
Study: 33732242

Group type: EXPERIMENTAL
Intervention: Dietary oxalate loading
Number of subjects: 0

Group type: COMPARATOR
Intervention: CaOx stone formers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxalate
Number of subjects: 0
Study: 33732892

Group type: EXPERIMENTAL
Intervention: μ-opioid agonist buprenorphine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: μ-opioid antagonist naltrexone
Number of subjects: 120

Group type: COMPARATOR
Intervention: inert pill
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: intermittent Theta Burst Stimulation (TBS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: continuous TBS
Number of subjects: 120

Group type: COMPARATOR
Intervention: sham TBS
Number of subjects: 120
Study: 33732977

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 922

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 922
Study: 33733328

Group type: EXPERIMENTAL
Intervention: Prefabricated brace
Number of subjects: 20
Study: 33733443

Group type: EXPERIMENTAL
Intervention: Stand-alone Xen45 gel stent implantation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Combined procedures with cataract surgery
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Emmetropic eyes (22.0 - 24.5 mm)
Number of subjects: 87
Study: 33733657

Group type: EXPERIMENTAL
Intervention: Dietary DHA intake
Number of subjects: 340
Study: 33733980

Group type: EXPERIMENTAL
Intervention: Netarsudil ophthalmic solution 0.02% prescribed once daily
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Netarsudil as monotherapy
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Netarsudil as concomitant therapy
Number of subjects: 261
Study: 33734005

Group type: EXPERIMENTAL
Intervention: Antigen quantitation of CD20, CD22, CD25, CD19, and %CD38(+) in CLL/SLL and MBL cases by flow cytometry.
Number of subjects: 208
Study: 33734088

Group type: EXPERIMENTAL
Intervention: C-IPU (clinic-based multidisciplinary therapy)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: O-IPU (online integrated multidisciplinary therapy)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: C-IPU
Number of subjects: 1090

Group type: COMPARATOR
Intervention: O-IPU
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Both programs
Number of subjects: 1090
Study: 33734135

Group type: EXPERIMENTAL
Intervention: Entecavir therapy
Number of subjects: 145
Study: 33734415

Group type: EXPERIMENTAL
Intervention: cRGDY-PEG-Cy5.5-nanoparticles (2 nmol, 0.4 mL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Technetium Tc 99m sulfur colloid (standard-of-care)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: cRGDY-PEG-Cy5.5-nanoparticles
Number of subjects: 24
Study: 33734431

Group type: EXPERIMENTAL
Intervention: Intentional endometrial injury
Number of subjects: 4035

Group type: COMPARATOR
Intervention: Hysteroscopy with endometrial injury
Number of subjects: 4035

Group type: EXPERIMENTAL
Intervention: Endometrial injury in early follicular phase (EFP)
Number of subjects: 4035

Group type: EXPERIMENTAL
Intervention: Endometrial injury in late follicular phase (LFP)
Number of subjects: 4035
Study: 33734451

Group type: EXPERIMENTAL
Intervention: Remote delivery of family-based therapy
Number of subjects: 0
Study: 33735015

Group type: EXPERIMENTAL
Intervention: Brief counselling strategies for smoking cessation and risky alcohol consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 33735176

Group type: EXPERIMENTAL
Intervention: Sickle cell disease (SCD) patients receiving specific treatment
Number of subjects: 872
Study: 33735386

Group type: EXPERIMENTAL
Intervention: DMPN group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 33735389

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (200 mg testosterone cypionate injected intramuscularly every 2 weeks for 18 months)
Number of subjects: 105
Study: 33735459

Group type: EXPERIMENTAL
Intervention: Neurological pupil index (NPi) assessed with a hand-held pupillometer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pupillary light reflex (PLR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SSEP)
Number of subjects: 50
Study: 33735476

Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg daily until relapse/intolerable toxicity)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2)
Number of subjects: 44
Study: 33735508

Group type: COMPARATOR
Intervention: Dornase alfa
Number of subjects: 2565
Study: 33735647

Group type: EXPERIMENTAL
Intervention: Preoperative symptoms of depression and anxiety
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Preoperative symptoms of depression
Number of subjects: 370
Study: 33736823

Group type: EXPERIMENTAL
Intervention: Ross procedure
Number of subjects: 2444
Study: 33737339

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 3 weeks)
Number of subjects: 615
Study: 33737338

Group type: EXPERIMENTAL
Intervention: OAd-MSCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of OAd-MSCs plus G-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 33737408

Group type: EXPERIMENTAL
Intervention: Screening for tuberculosis
Number of subjects: 0
Study: 33737431

Group type: EXPERIMENTAL
Intervention: Perioperative blood transfusions
Number of subjects: 0
Study: 33737439

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-like symptoms
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 testing
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Medication changes
Number of subjects: 1490
Study: 33737646

Group type: EXPERIMENTAL
Intervention: Infrequent iron supplement treatment
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Hb 10.6 g/dL cutoff
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Routine Hb testing between 24 and 30 gestational weeks
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Iron supplement
Number of subjects: 1527
Study: 33737935

Group type: EXPERIMENTAL
Intervention: Intravenous rhC1-INH 50 U/kg (maximum, 4,200 U)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pre-treatment phase (no rhC1-INH)
Number of subjects: 19
Study: 33737954

Group type: EXPERIMENTAL
Intervention: Daclizumab beta 150 mg subcutaneously every 4 weeks for up to 5 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon beta-1a (from DECIDE study)
Number of subjects: 0
Study: 33738451

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 29
Study: 33738485

Group type: EXPERIMENTAL
Intervention: Sickle cell trait (HbAS)
Number of subjects: 678

Group type: COMPARATOR
Intervention: Hemoglobin AA (HbAA)
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Asymptomatic parasitemia given infection
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 678
Study: 33738484

Group type: EXPERIMENTAL
Intervention: Parental pressure to eat
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Parental perceived stress
Number of subjects: 148
Study: 33738491

Group type: EXPERIMENTAL
Intervention: Adjuvant Ozone Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33738534

Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) - continuous scale
Number of subjects: 3435
Study: 33738543

Group type: EXPERIMENTAL
Intervention: Acute alcohol consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33738563

Group type: EXPERIMENTAL
Intervention: Intraoperative margin assessment using flexible autoradiography (FAR) with ≤ 300 MBq of scintillating film
Number of subjects: 88
Study: 33738626

Group type: EXPERIMENTAL
Intervention: Stage 3 AMD
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Presence of subretinal drusenoid deposits (SDD)
Number of subjects: 346
Study: 33738668

Group type: EXPERIMENTAL
Intervention: Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, combined with everolimus.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Everolimus (doses >5 mg).
Number of subjects: 0
Study: 33738774

Group type: EXPERIMENTAL
Intervention: Gla-300
Number of subjects: 46

Group type: COMPARATOR
Intervention: NPH
Number of subjects: 46
Study: 33738776

Group type: EXPERIMENTAL
Intervention: Health economic evaluation for the German healthcare system
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Informal care costs
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Hospitalization costs
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Direct costs
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Indirect costs
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Duration of the disease
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Costs in late stage of the disease
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Mean number of days in hospital and need for care
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Informal caregivers
Number of subjects: 228
Study: 33739136

Group type: EXPERIMENTAL
Intervention: Radially adjustable stentrievers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard stentrievers
Number of subjects: 0
Study: 33739292

Group type: EXPERIMENTAL
Intervention: Medication adherence program lasting 6 months
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Medication adherence program lasting 12 months
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Electronic monitors and pill counts for assessing medication adherence
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Generalized estimating equation multimodeling
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Qualitative interviews for patient satisfaction assessment
Number of subjects: 73
Study: 33739295

Group type: EXPERIMENTAL
Intervention: Instant messaging/social media follow-up system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 15
Study: 33739857

Group type: EXPERIMENTAL
Intervention: Glofitamab (0.005-30 mg)
Number of subjects: 171
Study: 33739956

Group type: EXPERIMENTAL
Intervention: Point-of-care lung ultrasound
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Point-of-care lung ultrasound for bronchiolitis/viral pneumonitis
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Point-of-care lung ultrasound for pneumonia
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Point-of-care lung ultrasound for status asthmaticus
Number of subjects: 88
Study: 33740028

Group type: EXPERIMENTAL
Intervention: Lineage B.1 (83.6%)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: SNP C15324T ('Basel cluster')
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Mass gathering event
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Travel returners and family transmissions
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis
Number of subjects: 746
Study: 33740049

Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitoring (isCGM)
Number of subjects: 851
Study: 33740052

Group type: EXPERIMENTAL
Intervention: Kynurenine:tryptophan ratio at 12 months
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Mannitol excretion at 6 months
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Plasma IGF-1 at 1 month
Number of subjects: 1169
Study: 33740157

Group type: EXPERIMENTAL
Intervention: Aminoglycoside therapy (amikacin, gentamicin, tobramycin)
Number of subjects: 931
Study: 33740205

Group type: EXPERIMENTAL
Intervention: Omission of surgery in complete responders to neoadjuvant chemotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Multidisciplinary involvement in trial design
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Foundational studies to predict complete pathologic response
Number of subjects: 18
Study: 33740420

Group type: EXPERIMENTAL
Intervention: Excessive exercise training over 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: World-class endurance athletes
Number of subjects: 0
Study: 33740734

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m² (C20)
Number of subjects: 2131

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m² (C25)
Number of subjects: 2131

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² (D75)
Number of subjects: 2131

Group type: EXPERIMENTAL
Intervention: Overall (C20, C25, D75)
Number of subjects: 2131
Study: 33740885

Group type: EXPERIMENTAL
Intervention: Intraoperative driving pressure (ΔP) in open abdominal surgery patients
Number of subjects: 2034

Group type: COMPARATOR
Intervention: Intraoperative driving pressure (ΔP) in closed abdominal surgery patients
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: Composite of postoperative pulmonary complications (PPCs)
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: Composite of intraoperative adverse events
Number of subjects: 2034
Study: 33740902

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg by 30-min intravenous administration every 12 weeks for up to 8 doses
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 128
Study: 33740903

Group type: EXPERIMENTAL
Intervention: ADHD+ (medicated)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ADHD- (medication-naïve)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 33740918

Group type: EXPERIMENTAL
Intervention: Exercise science students
Number of subjects: 993

Group type: COMPARATOR
Intervention: Reference students
Number of subjects: 993
Study: 33741071

Group type: EXPERIMENTAL
Intervention: Theory-based intervention consisting of an online video and patient recall process for medication reviews.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care provided by GP practices.
Number of subjects: 120
Study: 33741070

Group type: EXPERIMENTAL
Intervention: Community-based Qigong
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Internet-based Qigong
Number of subjects: 54

Group type: COMPARATOR
Intervention: Self-care control group
Number of subjects: 54
Study: 33741296

Group type: EXPERIMENTAL
Intervention: Eribulin 1.1 mg/m² in combination with avelumab
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Avelumab (fixed dose)
Number of subjects: 6
Study: 33741317

Group type: EXPERIMENTAL
Intervention: TAK-062 (100-900 mg)
Number of subjects: 0
Study: 33741321

Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Interleukin-8 (inflammation marker)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Total social support
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Hazardous drinking score
Number of subjects: 216
Study: 33741402

Group type: EXPERIMENTAL
Intervention: Cross-frequency transcranial alternating current stimulation (CF-tACS) during cognitive control task performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33741442

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 8, 10, 12, or 18 mg/kg on days 1 and 8 of 21-day cycles until disease progression or unacceptable toxicity
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 495
Study: 33741467

Group type: EXPERIMENTAL
Intervention: Deep regional hyperthermia scheduled twice weekly
Number of subjects: 78
Study: 33741641

Group type: EXPERIMENTAL
Intervention: Gastric per-oral endoscopic myotomy (G-POEM)
Number of subjects: 80
Study: 33741670

Group type: EXPERIMENTAL
Intervention: Hypothetical participation in an early phase CAR-T cell therapy trial
Number of subjects: 13
Study: 33741689

Group type: EXPERIMENTAL
Intervention: GDF-15 and ABC-AF-bleeding score
Number of subjects: 23718

Group type: EXPERIMENTAL
Intervention: GDF-15 and ABC-AF-death score
Number of subjects: 23718

Group type: EXPERIMENTAL
Intervention: ABC-AF-bleeding score
Number of subjects: 23718

Group type: EXPERIMENTAL
Intervention: ABC-AF-death score
Number of subjects: 23718
Study: 33741715

Group type: EXPERIMENTAL
Intervention: Inhibition of EWS-FLI1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of menin
Number of subjects: 0
Study: 33741739

Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 1030
Study: 33742027

Group type: EXPERIMENTAL
Intervention: Passive simulated jogging device (JD) used for 90 minutes per day for 7 days after an initial OGTT (Pre-JD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pre-JD OGTT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-JD OGTT
Number of subjects: 10
Study: 33742062

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic clamp to normalize serum glucose
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Baseline measurements in OT2D
Number of subjects: 23
Study: 33742104

Group type: EXPERIMENTAL
Intervention: Tumor genomic profiling and targeted agents
Number of subjects: 320
Study: 33742193

Group type: EXPERIMENTAL
Intervention: Weight Loss Maintainers (WLM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal Controls (NC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Overweight/Obesity Controls (OC)
Number of subjects: 26
Study: 33742208

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement with social and behavior change communication intervention
Number of subjects: 367

Group type: COMPARATOR
Intervention: Comparison district (no intervention)
Number of subjects: 367
Study: 33742249

Group type: EXPERIMENTAL
Intervention: Synthetic surgical glue to fix anterior and posterior meshes to the vagina
Number of subjects: 70
Study: 33742979

Group type: EXPERIMENTAL
Intervention: Atezolizumab (IMmotion 010; NCT03024996)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-564; NCT03142334)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nivolumab (PROSPER; NCT03055013)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nivolumab with or without ipilimumab (CheckMate 914; NCT03138512)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Durvalumab with or without tremelimumab (RAMPART; NCT03288532)
Number of subjects: 5
Study: 33743073

Group type: EXPERIMENTAL
Intervention: Metronomic oral vinorelbine (VRL; 30 mg/day)
Number of subjects: 9